IAVI and Biofabri are collaborating on the trial, which will recruit around 4,300 patients with latent TB infections across ...

Spanish biopharmaceutical company Biofabri and nonprofit scientific research organization IAVI announced today that the first ...

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of ...

Patna: Despite achieving more than 75% immunisation coverage for most vaccines, Bihar continues to struggle with low coverage ...

Researchers have engineered two mycobacterial strains with built-in kill switches that trigger self-destruction after immune ...

Innovative research at Weill Cornell Medicine introduces engineered mycobacteria strains with 'kill switches' for safer TB ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill switches" that can be triggered to stop the ...

The platform can be harnessed for TB, potentially improving protection and durability of immunity in a way that traditional ...

Commercial cattle farms in low-incidence bovine tuberculosis (TB) areas of England and Wales are being invited to participate ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.